moderate - Healthcare services demonstrate relative recession resilience as medical needs persist regardless of economic conditions, but Evolent faces cyclical pressures through two channels: (1) health plan clients may reduce discretionary spending on technology platforms during downturns, and (2) Medicaid redetermination cycles and employer-sponsored coverage losses during recessions can reduce lives under management. The company's value proposition of medical cost reduction becomes more attractive during economic stress, partially offsetting membership headwinds.

Rising interest rates create multiple headwinds: (1) higher borrowing costs on the company's debt (Debt/Equity of 1.29 suggests meaningful leverage), directly impacting interest expense and path to profitability, (2) valuation multiple compression for unprofitable growth companies as investors demand higher risk premiums, and (3) potential pressure on health plan clients' investment portfolios, reducing their willingness to invest in new technology platforms. The company's negative FCF profile makes it particularly vulnerable to tighter financial conditions.

growth - The company attracted growth investors based on 30% revenue growth and the secular trend toward value-based care, but severe underperformance (-73% annually) has likely shifted the holder base toward distressed/turnaround investors and momentum sellers. The combination of negative profitability, negative FCF, and high volatility makes this unsuitable for value or income investors. Current 0.2x Price/Sales suggests deep value territory, but requires belief in operational turnaround and path to profitability.